Sprint Bioscience is a preclinical-stage biotech company leveraging fragment-based drug discovery to develop novel oncology therapeutics. Its capital-efficient business model centers on advancing programs to a preclinical proof-of-concept before out-licensing them to larger pharma partners, as demonstrated by a major deal with Gilead Sciences. The company is expanding its pipeline into metabolic/inflammatory diseases through collaborations, aiming to address high-need areas with significant commercial potential.
OncologyMetabolic DiseasesInflammatory Diseases
Technology Platform
Fragment-based drug discovery (FBDD) platform for efficient identification and optimization of novel small molecule drug candidates.
Funding History
4
Total raised:$47.5M
Series C$20MIndustrifonden
Series B$15MIndustrifonden
Series A$10MKarolinska Development
Seed$2.5MKarolinska Development
Opportunities
The large, growing global oncology market and the high demand from pharma companies for novel, de-risked preclinical assets create a significant opportunity for successful out-licensing deals.
Expansion into metabolic/inflammatory diseases like MASH diversifies the pipeline and opens additional partnering avenues.
Risk Factors
The business model is entirely dependent on successfully out-licensing preclinical programs, which is highly competitive and subject to partner priorities.
There is inherent scientific risk that the fragment-based platform may fail to generate new compelling candidates or that programs may encounter preclinical failures.
Competitive Landscape
Sprint Bioscience competes with other preclinical biotechs and academic spin-outs seeking pharma partnerships, as well as the internal discovery efforts of large pharmaceutical companies. Its differentiation lies in its specialized fragment-based platform and capital-efficient model focused solely on early-stage asset creation.
